leisure time -WSS

leisure time

author：knowledge 2025-09-28 20:32:45 - browse：54

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Wikipedia

focus

WSS

Naloxone nonprofit donates 200,000 doses after FDA approval

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

American woman, child freed after being kidnapped in Haiti last month

Methadone doses haven’t kept up in the age of fentanyl

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

explore

leisure time

explore

Anesthesiologist group: stop taking Ozempic before surgery

Man killed during FBI raid in connection with threats against Biden, other officials

Affirmative action in medical school literally saved lives

Pregnancy ages women, but effects reverse after delivery

Affirmative action in medical school literally saved lives

With Wegovy coverage, Medicare patients may face high costs

Dobbs anniversary: the lost opportunity of abortion as health care

Bring on the sabbaticals for nurses

Moonlake's readout produced a cash windfall. Risks remain

Yancopoulos of Regeneron works to expand Dupixent success

leisure time

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

'Patient friction coefficient' can gauge a clinical trial's patient burden

Pregnancy ages women, but effects reverse after delivery

A biotech analyst on neuroscience, placebo effect, not over

FDA panel issues narrow recommendation for Covid vaccine booster doses

Wikipedia

focus

hotspot

explore